FDA Aimed For Level Playing Field With Ofev, Esbriet Labeling
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The agency tried not to give a marketing advantage to either Boehringer Ingelheim's Ofev or Roche subsidiary InterMune's Esbriet when it simultaneously approved the first two drugs for idiopathic pulmonary fibrosis.